The future for the treatment of genotype 4 chronic hepatitis C

Liver Int. 2012 Feb;32 Suppl 1:146-50. doi: 10.1111/j.1478-3231.2011.02704.x.

Abstract

Hepatitis C virus genotype 4 (HCV-4) is the most common type of hepatitis C virus (HCV) in the Middle East and Africa, in particular Egypt. Since the development of new protease inhibitors, the response of HCV-4 to the standard regimen of treatment (pegylated interferon/ribavirin) lags behind other genotypes and has become the most resistant type to treat. The development of therapeutic strategies for all patients with HCV-4 whether they are naïve, have experienced a virological breakthrough, are relapsers or non-responders is still a considerable challenge. New types of interferon (Consensus Interferon, Y-shaped, Albinterferon...) and new direct action antiviral drugs (Nitazoxanide, Vit.D, other) may improve the treatment of patients with HCV-4. The IL28B CC polymorphism may be associated with sustained virological response.

Publication types

  • Review

MeSH terms

  • Albumins / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Drug Therapy, Combination
  • Hepacivirus / drug effects
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Liver Cirrhosis / drug therapy*
  • Liver Cirrhosis / virology
  • Oligopeptides / therapeutic use
  • Polyethylene Glycols / therapeutic use
  • Proline / analogs & derivatives
  • Proline / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Ribavirin / therapeutic use
  • Serine Proteinase Inhibitors / therapeutic use*
  • Thiazoles / therapeutic use
  • Time Factors
  • Viral Load / drug effects
  • Vitamin D / therapeutic use

Substances

  • Albumins
  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Oligopeptides
  • Recombinant Proteins
  • Serine Proteinase Inhibitors
  • Thiazoles
  • Vitamin D
  • Polyethylene Glycols
  • Ribavirin
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline
  • peginterferon alfa-2b
  • peginterferon alfa-2a
  • nitazoxanide